Eisai's Banzel gets US approval and complete response letter for epilepsy

18 Nov 2008

• By Katie McQue

[C#198800610:Eisai]'santiconvulsant Banzel (rufinamide) has received approval from the US FDA as an adjunctive treatment for of seizures associated with a severe form of epilepsy, Lennox-Gastaut syndrome (LGS), in patients aged four years and older. It will be launched in the US in 2009.

Eisai'santiconvulsant Banzel (rufinamide) has received approval from the US FDA as an adjunctive treatment for of seizures associated with a severe form of epilepsy, Lennox-Gastaut syndrome (LGS), in patients aged four years and older. It will be launched in the US in 2009.

However, the FDA issued a complete response letter for Banzel as adjunctive therapy partial-onset seizures, with and without secondary generalisation...